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BACKGROUND
A simple treatment regimen that is effective in a broad range of patients who are 
chronically infected with the hepatitis C virus (HCV) remains an unmet medical need.
METHODS
We conducted a phase 3, double-blind, placebo-controlled study involving untreated 
and previously treated patients with chronic HCV genotype 1, 2, 4, 5, or 6 infection, 
including those with compensated cirrhosis. Patients with HCV genotype 1, 2, 4, 
or 6 were randomly assigned in a 5:1 ratio to receive the nucleotide polymerase 
inhibitor sofosbuvir and the NS5A inhibitor velpatasvir in a once-daily, fixed-dose 
combination tablet or matching placebo for 12 weeks. Because of the low preva-
lence of genotype 5 in the study regions, patients with genotype 5 did not undergo 
randomization but were assigned to the sofosbuvir–velpatasvir group. The primary 
end point was a sustained virologic response at 12 weeks after the end of therapy.
RESULTS
Of the 624 patients who received treatment with sofosbuvir–velpatasvir, 34% had 
HCV genotype 1a, 19% genotype 1b, 17% genotype 2, 19% genotype 4, 6% geno-
type 5, and 7% genotype 6. A total of 8% of patients were black, 19% had cirrhosis, 
and 32% had been previously treated for HCV. The rate of sustained virologic re-
sponse among patients receiving sofosbuvir–velpatasvir was 99% (95% confidence 
interval, 98 to >99). Two patients receiving sofosbuvir–velpatasvir, both with HCV 
genotype 1, had a virologic relapse. None of the 116 patients receiving placebo had 
a sustained virologic response. Serious adverse events were reported in 15 patients 
(2%) in the sofosbuvir–velpatasvir group and none in the placebo group.
CONCLUSIONS
Once-daily sofosbuvir–velpatasvir for 12 weeks provided high rates of sustained 
virologic response among both previously treated and untreated patients infected 
with HCV genotype 1, 2, 4, 5, or 6, including those with compensated cirrhosis. 
(Funded by Gilead Sciences; ClinicalTrials.gov number, NCT02201940.)
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The hepatitis C virus (HCV), a single-stranded RNA virus of the family Flavi-viridae with six major genotypes, infects 
up to 150 million people worldwide.1,2 Chronic 
HCV infection causes progressive liver fibrosis, 
which can lead to cirrhosis, hepatic decompen-
sation, and hepatocellular carcinoma.3,4 As many 
as half a million people die annually from liver 
disease associated with chronic HCV infection.5
In recent years, the development of drugs that 
directly interfere with HCV replication has revo-
lutionized HCV treatment. There are now effec-
tive combinations of direct-acting antiviral agents 
for most patients, but in choosing an appropri-
ate regimen, clinicians must take into account 
the patient’s treatment history, HCV genotype 
and subtype, stage of fibrosis, and, in some 
cases, patterns of antiviral resistance. Some 
regimens also include ribavirin, which has 
known hematologic and other side effects and 
is teratogenic.6,7 The development of a ribavirin-
free single-tablet regimen of short duration that 
is effective in a broad range of patients with 
HCV infection would simplify clinical decision 
making and reduce the need for pretreatment 
testing and monitoring during therapy.8
Sofosbuvir is a nucleotide analogue inhibitor 
of the HCV NS5B polymerase approved for the 
treatment of HCV in combination with a variety 
of other agents, including NS5A inhibitors, riba-
virin, and peginterferon–ribavirin. Velpatasvir 
(formerly GS-5816, Gilead Sciences) is a new 
pangenotypic HCV NS5A inhibitor with antiviral 
activity against HCV replicons in genotypes 1 
through 6.9-11 In phase 2 trials, the combination 
of 400 mg of sofosbuvir and 100 mg of velpatas-
vir with or without ribavirin resulted in high 
rates of sustained virologic response in a broad 
range of patients with HCV. These included pre-
viously treated and untreated patients, those with 
and without compensated cirrhosis, and those 
infected with HCV of all six genotypes.12,13 The 
inclusion of ribavirin did not appear to improve 
efficacy but was associated with a slightly in-
creased incidence of some adverse events, includ-
ing hematologic abnormalities.
We conducted a phase 3 trial (ASTRAL-1) to 
assess the efficacy and safety of 12 weeks of 
treatment with a fixed-dose combination of vel-
patasvir and sofosbuvir among both previously 
treated and untreated patients who were chroni-
cally infected with HCV genotype 1, 2, 4, 5, or 6, 
including those with compensated cirrhosis.
Me thods
Patients
We enrolled patients at 81 sites in the United 
States, Canada, Europe, and Hong Kong from 
July 18, 2014, through December 19, 2014. Eli-
gible patients were 18 years of age or older who 
had chronic infection with HCV genotype 1, 2, 
4, 5, or 6. All patients provided written informed 
consent.
The original clinical-development program 
for sofosbuvir–velpatasvir involved two trials — 
one in patients with HCV genotype 1, 2, 4, 5, or 6 
(ASTRAL-1) and one in patients with HCV geno-
type 3. A separate trial with an active compara-
tor group was deemed to be necessary for pa-
tients with HCV genotype 3 in light of the 
special clinical challenges presented in this 
population. After the protocol for the present 
study was finalized and trial activity had begun, 
the Food and Drug Administration requested a 
separate trial with an active comparator for pa-
tients with HCV genotype 2. Because enroll-
ment in the present study had already begun, 
we did not amend the protocol to exclude pa-
tients with HCV genotype 2. Therefore, two 
additional phase 3 trials were conducted to 
evaluate sofosbuvir–velpatasvir in patients with 
HCV genotype 2 (ASTRAL-2) and HCV geno-
type 3 (ASTRAL-3), and the results are reported 
now in the Journal.14,15
The protocol targeted an enrollment of ap-
proximately 20% of patients who had been pre-
viously treated for HCV with a regimen contain-
ing interferon and who had not had a sustained 
virologic response. Those who had discontinued 
previous HCV treatment because of an adverse 
event were not eligible. Patients who had previ-
ously received any nucleotide analogue HCV NS5B 
inhibitor or any NS5A inhibitor were not eligible. 
Approximately 20% of patients could have evi-
dence of cirrhosis, which was defined as liver-
biopsy results showing a Metavir fibrosis score 
of 4 or an Ishak score of 5 or more, a FibroTest 
score of more than 0.75 and a ratio of aspartate 
aminotransferase to platelets of more than 2, 
or a FibroScan reading of more than 12.5 kPa. 
There were no upper limits for age or body-mass 
index. Patients with a history of hepatic decom-
pensation or hepatocellular carcinoma were not 
eligible for enrollment. Full eligibility criteria 
are provided in the protocol, available with the 
full text of this article at NEJM.org.
A Quick Take 
is available at 
NEJM.org
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Study Design
In this multicenter, double-blind, placebo-con-
trolled trial, patients with HCV genotype 1, 2, 4, 
or 6 were randomly assigned in a 5:1 ratio to 
receive a fixed-dose combination tablet contain-
ing 400 mg of sofosbuvir and 100 mg of velpatas-
vir, administered orally once daily for 12 weeks, 
or a placebo tablet to match the active treatment 
once daily for 12 weeks. Patients in the placebo 
group were eligible for deferred treatment with 
12 weeks of sofosbuvir–velpatasvir. Randomiza-
tion was stratified according to genotype (1, 2, 4, 
6, or indeterminate) and the presence or absence 
of cirrhosis. Given the low prevalence of geno-
type 5 HCV infection in the regions in which the 
study was conducted, we targeted the enrollment 
of only 20 patients with HCV genotype 5. These 
patients did not undergo randomization but were 
enrolled in the sofosbuvir–velpatasvir group only.
Study Assessments
Serum HCV RNA was measured by means of the 
COBAS AmpliPrep/COBAS TaqMan HCV Quanti-
tative Test, version 2.0 (Roche Molecular Sys-
tems), with a lower limit of quantification of 
15 IU per milliliter. HCV genotype and subtype 
were determined with the use of the VERSANT 
HCV Genotype INNO-LiPA 2.0 assay (Siemens). 
IL28B genotyping was performed by means of 
polymerase-chain-reaction amplification and se-
quencing of the rs12979860 single-nucleotide 
polymorphism.
Assessments during treatment included stan-
dard laboratory testing, serum HCV RNA, vital 
signs, electrocardiography, and symptom-directed 
physical examinations. All adverse events were 
recorded and graded according to a standardized 
scale. (Details are provided in the study protocol.)
Deep sequencing of the target regions of vel-
patasvir and sofosbuvir, HCV NS5A and NS5B, 
respectively, was performed for all patients at 
baseline and again for all patients with virologic 
failure in samples obtained at the time of fail-
ure. The sequences from baseline samples were 
compared with those obtained at the time of 
virologic failure to detect emergent resistance-
associated variants. Resistance-associated vari-
ants that were present in more than 1% of se-
quence reads are reported.
End Points
The primary efficacy end point was the rate of 
sustained virologic response, which was defined 
as an HCV RNA level of less than 15 IU per 
milliliter at 12 weeks after the end of treatment 
in all patients who received at least one dose of 
sofosbuvir–velpatasvir or placebo. Secondary end 
points included the rate of adverse events and 
treatment discontinuations because of adverse 
events.
Study Oversight
This study was approved by the institutional re-
view board or independent ethics committee at 
each participating study site and was conducted 
in compliance with the Declaration of Helsinki, 
Good Clinical Practice guidelines, and local regu-
latory requirements. The study was designed and 
conducted by the sponsor (Gilead Sciences) in 
collaboration with the principal investigators. 
The sponsor collected the data, monitored study 
conduct, and performed the statistical analyses. 
An independent data and safety monitoring com-
mittee reviewed the progress and oversight of 
the study. The investigators, participating insti-
tutions, and sponsor agreed to maintain confi-
dentiality of the data. All the authors had access 
to the data and assume responsibility for the 
integrity and completeness of the reported data 
and fidelity to the protocol. The initial draft of 
the manuscript was prepared by a professional 
writer employed by Gilead Sciences and the first 
and last authors with input from all the authors.
Statistical Analysis
The primary efficacy analysis was designed to 
test for the superiority of the rate of sustained 
virologic response among patients receiving sofos-
buvir–velpatasvir to a prespecified performance 
goal of 85% by means of a two-sided exact one-
sample binomial test. This 85% rate was not a 
historical control derived from rates of sustained 
virologic response in prior HCV treatment trials, 
since it would not be possible to calculate a 
single historical rate for the different standard 
treatments recommended for the various geno-
types included in this study. Rather, it is a bench-
mark rate that is based on the general trend 
toward increasing rates of sustained virologic 
response in recent years and the general appeal 
of using a fixed, clinically relevant threshold as 
a measure of treatment benefit.16 We determined 
that the enrollment of 500 patients in the sofos-
buvir–velpatasvir group would provide a power of 
90% to detect an improvement of at least 5 per-
centage points in the rate of sustained virologic 
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response over the performance goal of 85%, on 
the basis of the two-sided exact one-sample bi-
nomial test at the 0.05 significance level. We 
used the Clopper–Pearson method to calculate 
point estimates and two-sided 95% exact confi-
dence intervals for rates of sustained virologic 
response for the sofosbuvir–velpatasvir group as 
a whole, as well as according to HCV genotype 
(1a, 1b, 2, 4, 5, or 6), and various subgroups.
The inclusion of a placebo group was de-
signed to provide the basis for evaluating the 
safety profile of sofosbuvir–velpatasvir in a 
population with expected coexisting medical 
conditions. We used a double-blind approach in 
the study-group assignments to ensure the elim-
ination of bias in assessments of safety. No 
formal comparison of safety between the groups 
was planned.
R esult s
Baseline Characteristics
Of the 847 patients who were initially screened, 
741 were enrolled and 706 underwent random-
ization; the 35 patients with genotype 5 infection 
were enrolled in the sofosbuvir–velpatasvir group, 
as prespecified (Table S1 and Fig. S1 in the Sup-
plementary Appendix, available at NEJM.org). One 
patient, who was lost to follow-up after undergo-
ing randomization to the sofosbuvir–velpatasvir 
group but before receiving treatment, was ex-
cluded from the safety and efficacy analyses.
The demographic and baseline clinical char-
acteristics of the 116 patients receiving placebo 
and the 624 patients receiving sofosbuvir–velpa-
tasvir were generally balanced (Table 1). In the 
sofosbuvir–velpatasvir group, 34% of the patients 
had HCV genotype 1a, 19% genotype 1b, 17% 
genotype 2, 19% genotype 4, 6% genotype 5, 
and 7% genotype 6. Most patients were white 
(79%) and male (60%). Nineteen percent of the 
patients had cirrhosis, 69% had a non-CC IL28B 
genotype (which has been associated with a re-
duced response to HCV treatment), and 32% had 
received previous unsuccessful treatment for HCV. 
Of the 201 patients in the sofosbuvir–velpatasvir 
group who had received previous treatment, 
28% had received a regimen of peginterferon, 
ribavirin, and a protease inhibitor, and 61% had 
received peginterferon and ribavirin; 48% of 
these patients had persistently detectable HCV 
RNA while receiving previous treatment, and 
51% had a virologic relapse or breakthrough. A 
total of 51% of patients were enrolled in Europe, 
46% in North America (Canada and the United 
States), and 3% in Hong Kong.
Efficacy
Overall, the rate of sustained virologic response 
among patients who received 12 weeks of sofos-
buvir-velpatasvir was 99% (95% confidence in-
terval [CI], 98 to >99), which was significantly 
superior to the prespecified performance goal of 
85% (P<0.001) (Table 2). None of the 116 pa-
tients in the placebo group had a sustained viro-
logic response.
Rates of sustained virologic response were 
similar regardless of the HCV genotype: 98% 
(95% CI, 95 to >99) in patients with genotype 1a 
infection, 99% (95% CI, 95 to 100) with genotype 
1b, 100% (95% CI, 97 to 100) with genotype 2, 
100% (95% CI, 97 to 100) with genotype 4, 97% 
(95% CI, 85 to >99) with genotype 5, and 100% 
(95% CI, 91 to 100) with genotype 6. Of the 121 
patients with any genotype who had cirrhosis, 
120 (99% [95% CI, 95 to >99]) had a sustained 
virologic response.
Of the 624 patients who received at least one 
dose of sofosbuvir–velpatasvir, 2 (<1%) had viro-
logic failure: a 56-year-old white man without 
cirrhosis who had received no previous treatment 
for genotype 1a HCV infection and a 58-year-old 
black man with cirrhosis who had persistently 
detectable HCV RNA during previous peginter-
feron–ribavirin treatment for genotype 1b HCV 
infection. The 2 men had undetectable serum 
HCV RNA at week 4 of treatment, and both had 
a virologic relapse by post-treatment week 4. 
Further details concerning these 2 patients are 
provided in Table S4 in the Supplementary Ap-
pendix.
Four other patients in the sofosbuvir–velpa-
tasvir group are not counted as having had a 
sustained virologic response. Two of the four 
were lost to follow-up (one did not return after 
completing 45 days of treatment; the other com-
pleted treatment and had undetectable serum 
HCV RNA at post-treatment week 4 but did not 
return for the post-treatment week 12 visit), one 
discontinued treatment because of an adverse 
event, and one died during follow-up. (Details 
regarding the last two patients are provided in 
the Safety subsection.)
Rates of sustained virologic response in all 
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Characteristic
Placebo 
(N = 116)
Sofosbuvir–Velpatasvir 
(N = 624)
Mean age (range) — yr 53 (25–74) 54 (18–82)
Male sex — no. (%) 68 (59) 374 (60)
Mean body-mass index (range)† 26 (18–40) 27 (17–57)
Race — no. (%)‡
White 90 (78) 493 (79)
Black 11 (9) 52 (8)
Asian 11 (9) 62 (10)
Other 4 (3) 14 (2)
Missing data 0 3 (<1)
Region — no. (%)
North America 52 (45) 289 (46)
Europe 60 (52) 316 (51)
Hong Kong 4 (3) 19 (3)
HCV genotype
1a 46 (40) 210 (34)
1b 19 (16) 118 (19)
2 21 (18) 104 (17)
4 22 (19) 116 (19)
5§ 0 35 (6)
6 8 (7) 41 (7)
HCV RNA
Mean — log10 IU/ml 6.3±0.58 6.3±0.66
≥800,000 IU/ml — no. (%) 87 (75) 461 (74)
IL28B genotype — no. (%)
CC 36 (31) 186 (30)
CT 53 (46) 339 (54)
TT 26 (22) 94 (15)
Missing data 1 (1) 5 (1)
Compensated cirrhosis — no. (%)¶ 21 (18) 121 (19)
Previous HCV treatment — no./total no.(%)
No 83/116 (72) 423/624 (68)
Yes 33/116 (28) 201/624 (32)
Protease inhibitor, peginterferon, and ribavirin 6/33 (18)  56/201 (28)
Peginterferon and ribavirin 24/33 (73) 122/201 (61)
Nonpegylated interferon with or without ribavirin 3/33 (9)  23/201 (11)
*  Plus–minus values are means ±SD. There were no significant differences between the groups.
†  The body-mass index is the weight in kilograms divided by the square of the height in meters.
‡  Race was self-reported.
§  Patients with genotype 5 HCV did not undergo randomization but were enrolled in the sofosbuvir–velpatasvir group.
¶  Cirrhosis was defined as one of the following: liver-biopsy results with a Metavir score of 4 or an Ishak score 5 or more, 
a FibroTest score of more 0.75 and a ratio of aspartate aminotransferase to platelets of more than 2, or a FibroScan 
value of more than 12.5 kPa. Patients with clinical evidence of decompensation (ascites, encephalopathy, or variceal 
hemorrhage) were excluded.
Table 1. Demographic Characteristics of the Patients at Baseline.*
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patient subgroups, including those with cirrho-
sis (99%) and prior treatment experience (>99%), 
were high (Tables S2 and S3 in the Supplemen-
tary Appendix).
Viral Resistance Testing
At baseline, NS5A resistance-associated variants 
were detected in 257 of 616 patients (42%) for 
whom sequencing data were available. Of these 
257 patients, 255 (99%) had a sustained viro-
logic response. The 2 patients who had virologic 
failure had NS5A-resistant variants at baseline 
and at the time of relapse. The patient with HCV 
genotype 1a infection who had a relapse had the 
Q30R variant in 2.6% of the viral population at 
baseline. At time of relapse, the Q30R variant 
was no longer present, but the Y93N variant was 
detected in more than 99% of the viral popula-
tion. The second patient (with HCV genotype 1b 
who had a relapse) had the Q30L variant (in 1.1% 
of the viral population), Q30R (in 98.7%), and 
L31M (in >99%) at baseline and Q30R (in >99%), 
L31M (in >99%), and Y93H (in 99%) at the time 
of relapse. The Q30R variant confers an increase 
by a factor of 2.2 in the 50% effective concentra-
tion (EC50) of velpatasvir in the HCV genotype 1a 
replicon. Arginine (R) variants at position 30 of 
the NS5A protein were present at baseline in 62 
patients in the entire study population: 5 patients 
with genotype 1, 5 with genotype 2, 50 with 
genotype 4, and 2 with genotype 5. Of these 62 
patients, 60 (97%) had a sustained virologic re-
sponse.
Variants associated with resistance to NS5B 
nucleoside inhibitors were detected at baseline 
in 54 of the 601 patients (9%) for whom sequenc-
ing data were available. No S282 variants were 
detected. All 54 patients had a sustained viro-
logic response.
Safety
Of the 624 patients in the sofosbuvir–velpatasvir 
group, 1 (<1%) discontinued treatment prema-
turely because of an adverse event. This patient, 
a 52-year-old white woman with genotype 1a 
HCV infection without cirrhosis, discontinued 
treatment because of an anxiety attack on the 
13th day of treatment. Of the 116 patients in the 
placebo group, 2 (2%) discontinued treatment 
because of an elevated aminotransferase level, a 
prespecified criterion for discontinuation.
A total of 15 patients (2%) in the sofosbuvir–
velpatasvir group had 19 serious adverse events 
(Table 3, and Table S5 in the Supplementary Ap-
pendix). No single serious adverse event occurred 
in more than 1 patient. There was one death in 
the sofosbuvir–velpatasvir group. This patient, a 
55-year-old white man with HCV genotype 5a 
without cirrhosis who had a history of dyslipid-
emia for which he was taking ezetimibe–simvas-
tatin, died during sleep 8 days after the comple-
tion of treatment. The cause of death was not 
determined. The patient was not taking amioda-
rone. None of the patients in the placebo group 
had a serious adverse event.
There was no significant difference in the 
rates of any adverse event in the sofosbuvir–vel-
patasvir group and the placebo group (78% and 
77%, respectively). The rates of individual ad-
verse events did not differ significantly between 
the two groups. The most common adverse events 
were headache, fatigue, nasopharyngitis, and 
nausea.
Response
Sofosbuvir–Velpatasvir 
(N = 624)
HCV RNA <15 IU/ml
During treatment period — no. (%)
At wk 2 355 (57)
At wk 4 564 (90)
At 12 wk after treatment period — no./total no. (%)
Any genotype 618/624 (99)
1a 206/210 (98)
1b 117/118 (99)
2 104/104 (100)
4 116/116 (100)
5  34/35 (97)
6   41/41 (100)
Virologic failure — no. (%)
During treatment 0
After treatment 2 (<1)
Other reason for classification as failure — no. (%)
Loss to follow-up 2 (<1)
Withdrawal of consent 1 (<1)
Death 1 (<1)
*  None of the patients receiving placebo had an HCV RNA level of less than 15 
IU per milliliter at any time point. Additional data about response according 
to subgroup are provided in Tables S2 and S3 in the Supplementary Appendix.
Table 2. Response during and after Treatment.*
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Hematologic abnormalities were infrequent 
in the sofosbuvir–velpatasvir group, affecting 
1% of patients or less. No patients in the placebo 
group had hematologic abnormalities (Table 3). 
No patient in either study group had a grade 3 
or 4 elevation in creatinine (>3.0 mg per deciliter 
[265 μmol per liter]) or total bilirubin (>2.5 mg 
per deciliter [43 μmol per liter]).
Discussion
Of the 170 million patients who are chronically 
infected with HCV worldwide, approximately 
half have HCV genotypes other than genotype 1, 
including about one third of patients with HCV 
in the United States.17 Currently approved regi-
mens of direct-acting antiviral agents are not 
equally effective across all genotypes, which 
means that testing to determine genotype and 
subtype is required before treatment can be ini-
tiated.6,7 A single combination regimen that is 
effective in all patients regardless of HCV geno-
type would obviate the need for pretreatment 
testing, which is an obstacle to treatment in re-
source-limited settings and may limit treatment 
uptake outside of specialty clinics.18
In this international, randomized, double-
blind, placebo-controlled phase 3 study, treat-
ment with sofosbuvir–velpatasvir for 12 weeks 
resulted in high rates of sustained virologic re-
sponse in patients with HCV genotype 1, 2, 4, 5, 
or 6, including those with cirrhosis and those 
who had received previous treatment and those 
who had not been treated. Virologic failure was 
rare in patients infected with HCV genotype 1, 
and there were no virologic failures among those 
with HCV genotype 2, 4, 5, or 6. The study pa-
tients, who were enrolled at 81 sites in eight 
countries, were diverse with respect to demo-
graphic and baseline characteristics. Patients with 
characteristics that are historically associated 
with a lower response to treatment — the pres-
ence of cirrhosis, prior treatment failure, black 
race, and non-CC genotype of IL28B — had rates 
of virologic response similar to those with his-
torically favorable characteristics.
The rate of sustained virologic response we 
observed in patients with HCV genotype 2 
(100%) was similar to that seen in a companion 
phase 3 trial14 reported in the Journal, in which 
99% of the patients with HCV genotype 2 in the 
sofosbuvir–velpatasvir group had a sustained 
virologic response. In a companion phase 3 trial 
reported in the same Journal article, 95% of the 
patients with HCV genotype 3 who received 
sofosbuvir–velpatasvir had a sustained virologic 
response, including 98% of previously untreated 
patients without cirrhosis, 93% of previously 
untreated patients with cirrhosis, 91% of previ-
ously treated patients without cirrhosis, and 89% 
of previously treated patients with cirrhosis.
The presence of baseline resistance-associated 
variants was not associated with virologic fail-
ure, which was represented in our study by two 
relapses and no virologic breakthrough. Although 
Event
Placebo 
(N = 116)
Sofosbuvir–
Velpatasvir 
(N = 624)
no. of patients (%)
Discontinuation of treatment owing  
to an adverse event
2 (2) 1 (<1)
Serious adverse event* 0 15 (2)
Any adverse event 89 (77) 485 (78)
Common adverse events†
Headache 33 (28) 182 (29)
Fatigue 23 (20) 126 (20)
Nasopharyngitis 12 (10) 79 (13)
Nausea 13 (11) 75 (12)
Insomnia 11 (9) 50 (8)
Diarrhea 8 (7) 48 (8)
Asthenia 9 (8) 41 (7)
Arthralgia 9 (8) 40 (6)
Cough 4 (3) 39 (6)
Back pain 11 (9) 29 (5)
Myalgia 6 (5) 25 (4)
Hematologic event
Hemoglobin level <10 g/dl 0 2 (<1)
Lymphocyte count 350 to <500 per mm3 0 3 (<1)
Neutrophil count 500 to <750 per mm3 0 4 (1)
Platelet count 25,000 to <50,000 per mm3 0 1 (<1)
*  No single serious adverse event occurred in more than 1 patient. In the sofos-
buvir–velpatasvir group, 15 patients had the following 19 serious adverse events: 
abscess limb, acute myocardial infarction, appendicitis, bronchitis, cellulitis, 
chronic obstructive pulmonary disease, epilepsy, extremity necrosis, gastro-
enteritis, influenza, ligament sprain, lung cancer, mania, palpitations, rotator-
cuff syndrome, small intestinal obstruction, sudden death from unknown 
cause, upper limb fracture, and vestibular neuronitis.
†  The listed adverse events occurred in at least 5% of the patients in any group.
Table 3. Discontinuations, Adverse Events, and Hematologic Abnormalities.
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the two patients who had a relapse had resis-
tance-associated variants at baseline and at the 
time of virologic failure, 99% of the patients 
with baseline NS5A resistance-associated vari-
ants had a sustained virologic response, which 
suggests that pretreatment testing for resistance-
associated variants is probably of little clinical 
value with sofosbuvir–velpatasvir.
Serious adverse events occurred in 2% of pa-
tients in the sofosbuvir–velpatasvir group and in 
no patients in the placebo group. No single seri-
ous adverse event occurred in more than one 
patient who received sofosbuvir–velpatasvir. The 
type, frequency, and severity of nonserious ad-
verse events were generally similar in the two 
study groups. Hematologic abnormalities occurred 
infrequently in patients receiving sofosbuvir–
velpatasvir (≤1% of patients). No patients receiv-
ing placebo had hematologic abnormalities.
A factor limiting the generalizability of our 
results is that we did not enroll patients in cer-
tain regions where the less common HCV geno-
types and subtypes are highly prevalent. In addi-
tion, we excluded patients with HCV genotype 3 
and those with decompensated cirrhosis, but 
these patients are being evaluated in parallel 
phase 3 studies14,15 that are reported now in the 
Journal. Also, patients who had previous treat-
ment failure with sofosbuvir or an NS5A-con-
taining regimen were excluded from the study.
In conclusion, treatment with the single-tablet 
regimen of sofosbuvir–velpatasvir for 12 weeks 
was highly effective for a broad range of patients 
with HCV genotype 1, 2, 4, 5, or 6 infection. The 
treatment was also effective among patients 
with compensated cirrhosis.
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